RASolute 302 Trial: A New Era for RAS-Targeted Drug Discovery

When the first Kaplan-Meier curve from the Phase 3 RASolute 302 trial appeared on the screens at the 2026 ASCO Plenary Session, the room didn’t just applaud — it stood, and some attendees were reportedly in tears.